294 related articles for article (PubMed ID: 26023778)
1. An Open Label Non-inferiority Trial Assessing Vibriocidal Response of a Killed Bivalent Oral Cholera Vaccine Regimen following a Five Year Interval in Kolkata, India.
Kanungo S; Desai SN; Saha J; Nandy RK; Sinha A; Kim DR; Bannerjee B; Manna B; Yang JS; Ali M; Sur D; Wierzba TF
PLoS Negl Trop Dis; 2015 May; 9(5):e0003809. PubMed ID: 26023778
[TBL] [Abstract][Full Text] [Related]
2. Flexibility of oral cholera vaccine dosing-a randomized controlled trial measuring immune responses following alternative vaccination schedules in a cholera hyper-endemic zone.
Kanungo S; Desai SN; Nandy RK; Bhattacharya MK; Kim DR; Sinha A; Mahapatra T; Yang JS; Lopez AL; Manna B; Bannerjee B; Ali M; Dhingra MS; Chandra AM; Clemens JD; Sur D; Wierzba TF
PLoS Negl Trop Dis; 2015 Mar; 9(3):e0003574. PubMed ID: 25764513
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of the killed bivalent (O1 and O139) whole-cell cholera vaccine in the Philippines.
Capeding MRZ; Gonzales MLAM; Dhingra MS; D'Cor NA; Midde VJ; Patnaik BN; Thollot Y; Desauziers E
Hum Vaccin Immunother; 2017 Oct; 13(10):2232-2239. PubMed ID: 28910563
[TBL] [Abstract][Full Text] [Related]
4. Bivalent oral cholera vaccine in participants aged 1 year and older in the Dominican Republic: A phase III, single-arm, safety and immunogenicity trial.
Cordero De Los Santos L; Feris-Iglesias J; Aloysia D'Cor N; Midde VJ; Patnaik BN; Thollot Y; Rasuli A; Desauziers E
Hum Vaccin Immunother; 2018 Jun; 14(6):1403-1411. PubMed ID: 29470934
[TBL] [Abstract][Full Text] [Related]
5. Induction of systemic, mucosal and memory antibody responses targeting Vibrio cholerae O1 O-specific polysaccharide (OSP) in adults following oral vaccination with an oral killed whole cell cholera vaccine in Bangladesh.
Akter A; Dash P; Aktar A; Jahan SR; Afrin S; Basher SR; Hakim A; Lisa AK; Chowdhury F; Khan AI; Xu P; Charles RC; Kelly M; Kováč P; Harris JB; Bhuiyan TR; Calderwood SB; Ryan ET; Qadri F
PLoS Negl Trop Dis; 2019 Aug; 13(8):e0007634. PubMed ID: 31369553
[TBL] [Abstract][Full Text] [Related]
6. Augmented immune responses to a booster dose of oral cholera vaccine in Bangladeshi children less than 5 years of age: Revaccination after an interval of over three years of primary vaccination with a single dose of vaccine.
Chowdhury F; Bhuiyan TR; Akter A; Bhuiyan MS; Khan AI; Tauheed I; Ahmed T; Ferdous J; Dash P; Basher SR; Hakim A; Lynch J; Kim JH; Excler JL; Kim DR; Clemens JD; Qadri F
Vaccine; 2020 Feb; 38(7):1753-1761. PubMed ID: 31879124
[TBL] [Abstract][Full Text] [Related]
7. Immune responses following one and two doses of the reformulated, bivalent, killed, whole-cell, oral cholera vaccine among adults and children in Kolkata, India: a randomized, placebo-controlled trial.
Kanungo S; Paisley A; Lopez AL; Bhattacharya M; Manna B; Kim DR; Han SH; Attridge S; Carbis R; Rao R; Holmgren J; Clemens JD; Sur D
Vaccine; 2009 Nov; 27(49):6887-93. PubMed ID: 19761838
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of a killed whole-cell oral cholera vaccine in Bangladesh: further follow-up of a cluster-randomised trial.
Ali M; Qadri F; Kim DR; Islam MT; Im J; Ahmmed F; Khan AI; Zaman K; Marks F; Kim JH; Clemens JD
Lancet Infect Dis; 2021 Oct; 21(10):1407-1414. PubMed ID: 34146473
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of oral killed whole cell recombinant B subunit cholera vaccine in Barranquilla, Colombia.
Concha A; Giraldo A; Castañeda E; Martínez M; de la Hoz F; Rivas F; Depetris A; Svennerholm AM; Sack DA
Bull Pan Am Health Organ; 1995 Dec; 29(4):312-21. PubMed ID: 8605522
[TBL] [Abstract][Full Text] [Related]
10. A Randomized, Placebo-Controlled Trial Evaluating Safety and Immunogenicity of the Killed, Bivalent, Whole-Cell Oral Cholera Vaccine in Ethiopia.
Desai SN; Akalu Z; Teshome S; Teferi M; Yamuah L; Kim DR; Yang JS; Hussein J; Park JY; Jang MS; Mesganaw C; Taye H; Beyene D; Bedru A; Singh AP; Wierzba TF; Aseffa A
Am J Trop Med Hyg; 2015 Sep; 93(3):527-533. PubMed ID: 26078323
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine in adults and children in Vellore, South India.
Raghava Mohan V; Raj S; Dhingra MS; Aloysia D'Cor N; Singh AP; Saluja T; Kim DR; Midde VJ; Kim Y; Vemula S; Narla SK; Sah B; Ali M
PLoS One; 2019; 14(6):e0218033. PubMed ID: 31211792
[TBL] [Abstract][Full Text] [Related]
12. A randomized, placebo-controlled trial of the bivalent killed, whole-cell, oral cholera vaccine in adults and children in a cholera endemic area in Kolkata, India.
Mahalanabis D; Lopez AL; Sur D; Deen J; Manna B; Kanungo S; von Seidlein L; Carbis R; Han SH; Shin SH; Attridge S; Rao R; Holmgren J; Clemens J; Bhattacharya SK
PLoS One; 2008 Jun; 3(6):e2323. PubMed ID: 18523643
[TBL] [Abstract][Full Text] [Related]
13. A randomized, non-inferiority trial comparing two bivalent killed, whole cell, oral cholera vaccines (Euvichol vs Shanchol) in the Philippines.
Baik YO; Choi SK; Olveda RM; Espos RA; Ligsay AD; Montellano MB; Yeam JS; Yang JS; Park JY; Kim DR; Desai SN; Singh AP; Kim IY; Kim CW; Park SN
Vaccine; 2015 Nov; 33(46):6360-5. PubMed ID: 26348402
[TBL] [Abstract][Full Text] [Related]
14. Vibriocidal antibody responses to a bivalent killed whole-cell oral cholera vaccine in a phase III trial in Kolkata, India.
Kanungo S; Lopez AL; Ali M; Manna B; Kim DR; Mahapatra T; Holmgren J; Dhingra MS; Weirzba TF; Nair GB; Bhattacharya SK; Clemens JD; Sur D
PLoS One; 2014; 9(5):e96499. PubMed ID: 24800828
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity of a killed bivalent (O1 and O139) whole cell oral cholera vaccine, Shanchol, in Haiti.
Charles RC; Hilaire IJ; Mayo-Smith LM; Teng JE; Jerome JG; Franke MF; Saha A; Yu Y; Kováč P; Calderwood SB; Ryan ET; LaRocque RC; Almazor CP; Qadri F; Ivers LC; Harris JB
PLoS Negl Trop Dis; 2014 May; 8(5):e2828. PubMed ID: 24786645
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity study of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine Shanchol, in Bangladeshi adults and children as young as 1 year of age.
Saha A; Chowdhury MI; Khanam F; Bhuiyan MS; Chowdhury F; Khan AI; Khan IA; Clemens J; Ali M; Cravioto A; Qadri F
Vaccine; 2011 Oct; 29(46):8285-92. PubMed ID: 21907255
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity of a killed bivalent whole cell oral cholera vaccine in forcibly displaced Myanmar nationals in Cox's Bazar, Bangladesh.
Chowdhury F; Bhuiyan TR; Akter A; Bhuiyan MS; Khan AI; Hossain M; Tauheed I; Ahmed T; Islam S; Rafique TA; Siddique SA; Harun NB; Islam K; Clemens JD; Qadri F
PLoS Negl Trop Dis; 2020 Mar; 14(3):e0007989. PubMed ID: 32176695
[TBL] [Abstract][Full Text] [Related]
18. Transient Intestinal Colonization by a Live-Attenuated Oral Cholera Vaccine Induces Protective Immune Responses in Streptomycin-Treated Mice.
Fakoya B; Sit B; Waldor MK
J Bacteriol; 2020 Nov; 202(24):. PubMed ID: 32540930
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and Protection From a Single Dose of Internationally Available Killed Oral Cholera Vaccine: A Systematic Review and Metaanalysis.
Lopez AL; Deen J; Azman AS; Luquero FJ; Kanungo S; Dutta S; von Seidlein L; Sack DA
Clin Infect Dis; 2018 Jun; 66(12):1960-1971. PubMed ID: 29177437
[TBL] [Abstract][Full Text] [Related]
20. Investigations into the safety and immunogenicity of a killed oral cholera vaccine developed in Viet Nam.
Trach DD; Cam PD; Ke NT; Rao MR; Dinh D; Hang PV; Hung NV; Canh DG; Thiem VD; Naficy A; Ivanoff B; Svennerholm AM; Holmgren J; Clemens JD
Bull World Health Organ; 2002; 80(1):2-8. PubMed ID: 11884967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
